TX-DENTALMONITORING
4.10.2021 16:09:05 CEST | Business Wire | Press release
DentalMonitoring, the company that pioneered artificial intelligence in dental and orthodontic care, is thrilled to announce the launch of the ScanBoxpro .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004005610/en/
Built upon the success of their previous DM ScanBox, their latest FDA-registered innovation is a portable device patients can take with them for precise AI-powered scans anywhere and anytime. This hardware accompanies the flagship software solution DentalMonitoring, a customizable cloud-based platform for remote clinical monitoring of orthodontic treatments designed to create a single automated workflow per patient and boost practice scalability.
The device consists of two components — a cheek retractor tube designed to draw the cheeks and lips from the buccal and labial surfaces of the teeth and gums during scanning and a phone holder designed to accommodate a smartphone.
Paired with the unique DM app for patients, the ScanBoxpro offers:
- Consistent imaging over time for precise tracking of treatment progress including aligners, braces and retainers of all brands
- Excellent occlusal and lateral views, including molar occlusion
- Increased portability
- Suited for all patients from 6 years old.
- Easy storage capability with 41% less volume
- Autoclavable capacity
“We couldn’t be prouder to introduce our latest innovation as we continue to go further and break new ground with our solutions,” says Phillipe Salah, CEO of DentalMonitoring. “The ScanBoxpro is a game-changer for patients. It’s lightweight, portable and can easily join them on-the-go, anywhere, for high-quality scans powered by the first and most robust AI in the industry. In turn, it allows doctors to have control at every stage of treatment and helps automate their workflow while enhancing their patient experiences.”
The ScanBoxpro is the newest addition to DentalMonitoring’s family of devices and software solutions including SmileMate, for engagement, triage and patient conversion and DentalMonitoring, the only available AI-based remote monitoring solution available to both fixed and removable orthodontic appliances of all brands.
About DentalMonitoring
DentalMonitoring was started with a simple idea: oral care should be connected and continuous — even outside the practice. Since then, the company has developed cutting edge algorithms based on the industry's largest image database that perform high-level AI analysis, calculate tooth movement remotely, and create photo-realistic simulations.
Their suite of solutions is a fully scalable, AI-powered platform giving providers the insights needed to modernize dental care. Backed by the industry’s largest AI database, the platform and patented technology allows doctors to detect and monitor oral observations remotely, optimizing in-person appointments. Smarter remote care breaks barriers to treatment for patients, and practices can broaden their presence with smarter care.
More information: www.dental-monitoring.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211004005610/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom